NTM in Oncology: Dual Beta-Lactam Signals Warrant Study
This single-center cohort characterizes nontuberculous mycobacterial epidemiology, susceptibility, and real-world treatment (including meropenem-based dual beta-lactam therapy) in cancer patients, an area with sparse pharmacotherapy data.
📅 Journal publication: Aug 2026(online Jul 29, 2026)·Last updated: Aug 12, 2026
NTM infections in cancer patients demand complex treatment approaches.
Nontuberculous mycobacteria (NTM) infections are increasing, and oncology patients represent a unique population at risk. 93 patients were studied, with Mycobacterium avium complex and Mycobacterium abscessus as common pathogens. 53% received therapy, often requiring regimen modifications. The findings highlight treatment challenges in oncology patients, noting dual β-lactam therapy's role. Limitations include the single-center retrospective design. NTM infections in oncology require complex, adaptive treatment strategies.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Pasikhova Y, Snyder M, Morrison A, Handley G, Syed M, Cannella AP
Citation:Pasikhova Y, Snyder M, Morrison A, et al. Nontuberculous Mycobacterial Infections at a National Cancer Institute-Designated Comprehensive Cancer Center in Florida. Open forum infectious diseases. 2026;13(8):ofag467. doi:10.1093/ofid/ofag467